Pfizer
3Q Revenues: $13.2 billion (+1%)
3Q Earnings: $2.7 billion (+110%)
YTD Revenues: $38.8 billion (+1%)
YTD Earnings: $9.0 billion (+40%)
Comments: Innovative Health sales in the quarter were $8.1 billion, up 11%, with growth from key brands including Ibrance and Eliquis, the addition of Xtandi revenues in the U.S. from the September 2016 acquisition of Medivation, as well as Lyrica and Xeljanz, primarily in the U.S. Global Ibrance revenues increased 59% operationally while global operational revenue growth for Eliquis and Xeljanz was 43% and 49%, respectively. Essential health sales were $5.1 billion, down 11% due to the February 2017 divestiture of Hospira Infusion Systems, a 22% operational decline from Peri-LOE Products, a 12% operational decline from the Sterile Injectable Pharmaceuticals (SIP) portfolio, primarily due to legacy Hospira product shortages in the U.S. These declines were partially offset by 70% growth from Biosimilars to $141 million. Lyrica IH sales were up 11% in the quarter to $1.2 billion. Eliquis alliance revenues and direct sales were $644 million, up 43%. Prevnar 13 sales were down 1% to $1.5 billion. Ibrance sales were $878 million, up 60%. Enbrel (Outside the U.S. and Canada) were $613 million, down 13%. Lipitor sales were up 16% to $491 million. Consumer health sales were $829 million, up 4%.